Rachel Stewart
Family · Pittsburgh, PANPI 1184081218
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.7% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $613, 5.2 times the $117 reported in 2022.
Across 72 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$302
- Mayne Pharma Commercial LLC$241
- Sage Therapeutics, LLC$215
- Astellas Pharma US Inc$210
- Exeltis, USA Inc.$106
- Cumberland Pharmaceuticals, Inc.$93
- plus $204 from 8 others
What the payments were for
- Food & beverage$1,27093%
- Education$1007%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 14 | $302 |
| Mayne Pharma Commercial LLC | 15 | $241 |
| Sage Therapeutics, LLC | 13 | $215 |
| Astellas Pharma US Inc | 8 | $210 |
| Exeltis, USA Inc. | 6 | $106 |
| Cumberland Pharmaceuticals, Inc. | 5 | $93 |
| Millicent US Inc | 3 | $57 |
| Sumitomo Pharma America, Inc. | 2 | $41 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Conmed Corporation | 1 | $20 |
| Merck | 1 | $19 |
| Pfizer | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| AbbVie | 1 | $13 |
How this compares
$1,370 in reported general payments places this provider in the 75th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 23 | $1,689 |
| Medroxyprogesterone Acetate | 14 | $676 |
| ValacyclovirValacyclovir Hcl | 24 | $501 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 32 | $318 |
| Nystatin | 13 | $134 |
| Fluconazole | 14 | $56 |
Paid to pharmacies, not to this prescriber.
Other family in Pittsburgh
- Kathleen ScholzPittsburgh$397K
- Kweilynn GreenePittsburgh$139K
- Margaret RosenzweigPittsburgh$89K
- Patricia HabdasPittsburgh$83K
- Morgan ColePittsburgh$41K
- Amber GrinnellPittsburgh$33K
- Matthew BarnesPittsburgh$25K
- Alexander TatangeloPittsburgh$20K
- Sydney MurrayPittsburgh$19K
- Renee ConnPittsburgh$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.